Literature DB >> 2860501

Clinical viral infections and multiple sclerosis.

W A Sibley, C R Bamford, K Clark.   

Abstract

Over an 8 year period, 170 patients with multiple sclerosis (MS) and 134 healthy controls were assessed at monthly intervals in order to ascertain environmental factors which might be important in producing exacerbation or progression of the illness, and to compare the frequency of common viral infections in the two groups. During cumulative periods designated "at risk" (2 weeks before the onset of infection until 5 weeks afterwards) annual exacerbation rates were almost 3-fold greater than those during periods not at risk. Approximately 9% of infections were temporally related to exacerbations, whereas 27% of exacerbations were related to infections. Frequency of common infections was approximately 20-50% less in MS patients than controls; it was progressively less in those with greater disability. Even in minimally disabled patients with similar potential for infectious contacts, the infection rate was significantly less than in controls, suggesting that MS patients could have superior immune defences against common viruses.

Entities:  

Mesh:

Year:  1985        PMID: 2860501      PMCID: PMC7173199          DOI: 10.1016/s0140-6736(85)92801-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  8 in total

1.  PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS.

Authors:  G A SCHUMACHER; G BEEBE; R F KIBLER; L T KURLAND; J F KURTZKE; F MCDOWELL; B NAGLER; W A SIBLEY; W W TOURTELLOTTE; T L WILLMON
Journal:  Ann N Y Acad Sci       Date:  1965-03-31       Impact factor: 5.691

2.  INFECTION AND IMMUNIZATION IN MULTIPLE SCLEROSIS.

Authors:  W A SIBLEY; J M FOLEY
Journal:  Ann N Y Acad Sci       Date:  1965-03-31       Impact factor: 5.691

3.  On the evaluation of disability in multiple sclerosis.

Authors:  J F KURTZKE
Journal:  Neurology       Date:  1961-08       Impact factor: 9.910

Review 4.  Recurrent viral infection (reinfection).

Authors:  T W Chang
Journal:  N Engl J Med       Date:  1971-04-08       Impact factor: 91.245

5.  Anesthesia in multiple sclerosis.

Authors:  C Bamford; W Sibley; J Laguna
Journal:  Can J Neurol Sci       Date:  1978-02       Impact factor: 2.104

6.  Seasonal variation of multiple sclerosis exacerbations in Arizona.

Authors:  C R Bamford; W A Sibley; C Thies
Journal:  Neurology       Date:  1983-06       Impact factor: 9.910

7.  Trauma as an etiologic and aggravating factor in multiple sclerosis.

Authors:  C R Bamford; W A Sibley; C Thies; J F Laguna; M S Smith; K Clark
Journal:  Neurology       Date:  1981-10       Impact factor: 9.910

8.  Swine influenza vaccination in patients with multiple sclerosis.

Authors:  C R Bamford; W A Sibley; J F Laguna
Journal:  Arch Neurol       Date:  1978-04
  8 in total
  160 in total

1.  The distinction blurs between an autoimmune versus microbial hypothesis in multiple sclerosis.

Authors:  D A Hafler
Journal:  J Clin Invest       Date:  1999-09       Impact factor: 14.808

Review 2.  The genetic epidemiology of multiple sclerosis.

Authors:  A Compston
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-10-29       Impact factor: 6.237

3.  Breakdown of the blood-retinal barrier induced by activated T cells of nonneural specificity.

Authors:  P Hu; J D Pollard; T Chan-Ling
Journal:  Am J Pathol       Date:  2000-04       Impact factor: 4.307

Review 4.  Human herpesvirus 6 infection as a trigger of multiple sclerosis.

Authors:  Konstantine I Voumvourakis; Dimitrios K Kitsos; Sotirios Tsiodras; George Petrikkos; Eleftherios Stamboulis
Journal:  Mayo Clin Proc       Date:  2010-10-06       Impact factor: 7.616

5.  The relevance of animal models in multiple sclerosis research.

Authors:  Aleksandar Denic; Aaron J Johnson; Allan J Bieber; Arthur E Warrington; Moses Rodriguez; Istvan Pirko
Journal:  Pathophysiology       Date:  2011-02

6.  Smoking: effects on multiple sclerosis susceptibility and disease progression.

Authors:  Dean M Wingerchuk
Journal:  Ther Adv Neurol Disord       Date:  2012-01       Impact factor: 6.570

Review 7.  Mechanisms of action of ACTH in the management of relapsing forms of multiple sclerosis.

Authors:  Regina Berkovich; Mark A Agius
Journal:  Ther Adv Neurol Disord       Date:  2014-03       Impact factor: 6.570

Review 8.  Neuroimmune interactions in a model of multiple sclerosis.

Authors:  C Jane Welsh; Andrew J Steelman; Wentao Mi; Colin R Young; Ralph Storts; Thomas H Welsh; Mary W Meagher
Journal:  Ann N Y Acad Sci       Date:  2009-02       Impact factor: 5.691

9.  Gamma interferon is critical for resistance to Theiler's virus-induced demyelination.

Authors:  M Rodriguez; K Pavelko; R L Coffman
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

Review 10.  Infection risk in patients on multiple sclerosis therapeutics.

Authors:  Eric M Williamson; Joseph R Berger
Journal:  CNS Drugs       Date:  2015-03       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.